Physicians
When the clinical picture is incomplete, urine metabolomics adds clarity.
Standard post-transplant monitoring has several gaps: surveillance biopsy is invasive, and routine labs like serum creatinine are non-specific lagging indicators of injury.
myOLARIS® -KTdx is a urine-based approach designed to help fill that space by supporting graft injury surveillance and adding context when standard signals leave the picture incomplete.
Biopsy remains the gold standard to differentiate types of graft injury. But the decision when to biopsy isn’t always straightforward. myOLARIS® -KTdx is intended to help inform that decision, offering a non-invasive signal that can support the clinical reasoning you’re already doing.
Where this fits
myOLARIS® -KTdx gives clinicians a similarity-based score indicating whether a patient's immune response is stable, trending toward under-immunosuppression (rejection risk), or toward over-immunosuppression (infection risk). The surveillance tool flags when clinical intervention may be warranted.
How myOLARIS® -KTdx works in practice
In a clinical setting, a patient provides a urine sample. The sample is temperature-controlled and shipped to Olaris for NMR-based metabolite profiling. A proprietary learning algorithm interprets the data, and we send a report to the ordering clinician. The turnaround time is about 3-5 business days.
Anil Chandraker
MD, FASN, FAST, FRCP
University of Massachusetts Chan School of Medicine, UMass Memorial Health Care
“We can quite easily over-immunosuppress our patient population. The use of metabolomics to profile a transplanted kidney could reveal a lot about the detailed processes occurring within the kidney. It could provide signatures of over- and under-immunosuppression. myOLARIS® -KTdx could be very useful in helping us tailor the immune suppression in our transplanted patient population."
Operations and compliance
myOLARIS® -KTdx is processed through a CLIA-certified laboratory. If you need practical review details such as sample handling, report format, and turnaround time, contact us.
myOLARIS® -KTdx snapshot for physicians
If you need to bring Olaris information back to your institution, start here.
What it is
myOLARIS® -KTdx is a non-invasive, urine-based laboratory-developed test (LDT) designed to support surveillance of kidney graft injury, including borderline rejection, subclinical and clinical rejection, and polyomavirus-associated nephropathy (PVAN).
PLA Code
The American Medical Association granted a unique PLA code (0542U) for the myOLARIS® -KTdx, effective April 1, 2025.
Sample and platform
Urine sample. NMR-based metabolite profiling with algorithmic interpretation.
What the result provides:
A similarity-based score intended to be interpreted by a licensed clinician in a clinical context.
How it differs from genetic blood tests (summary)
Most cfDNA tests or genetic expression profiles tests have been optimized to rule out rejection. The urine-based myOLARIS® -KTdx test uses a similarity-based score to identify stable, borderline, rejection and PVAN with more phenotypes to come.
Operations and compliance
Processed through a CLIA-certified laboratory.
Evidence for review to Publications and Presentations
View our peer-reviewed publications and related scientific materials
Turnaround time
About 3-5 business days from receipt of the sample.
Coding Support
Commonly selected ICD-10 codes include: T86.10, T86.19, Z48.22, Z94.0, T86.13.
Ready to Learn More About Olaris?
Contact us for practical implementation materials and a walkthrough of the report format.